Ascendis Pharma A/S (NASDAQ:ASND) has been given a $50.00 target price by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Wednesday, January 3rd. The brokerage presently has a “buy” rating on the biotechnology company’s stock. JPMorgan Chase & Co.’s target price indicates a potential downside of 6.84% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Bank of America boosted their price target on Ascendis Pharma A/S from $36.00 to $46.00 in a research note on Thursday, September 28th. Credit Suisse Group reiterated an “outperform” rating and issued a $50.00 price target (up previously from $30.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Wedbush reiterated an “outperform” rating and issued a $10.71 price target (down previously from $65.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Finally, HC Wainwright reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, December 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $43.29.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at $53.67 on Wednesday. Ascendis Pharma A/S has a 1 year low of $19.95 and a 1 year high of $55.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, November 16th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.37). Ascendis Pharma A/S had a negative net margin of 4,687.42% and a negative return on equity of 64.10%. analysts forecast that Ascendis Pharma A/S will post -3.88 EPS for the current year.

A number of hedge funds have recently modified their holdings of ASND. Bank of Montreal Can grew its holdings in Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock worth $126,000 after buying an additional 2,541 shares in the last quarter. California Public Employees Retirement System bought a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $430,000. VHCP Management II LLC grew its holdings in Ascendis Pharma A/S by 21.6% in the 2nd quarter. VHCP Management II LLC now owns 986,492 shares of the biotechnology company’s stock worth $27,385,000 after buying an additional 175,000 shares in the last quarter. Janus Henderson Group PLC bought a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $15,403,000. Finally, DAFNA Capital Management LLC grew its holdings in Ascendis Pharma A/S by 82.4% in the 2nd quarter. DAFNA Capital Management LLC now owns 33,214 shares of the biotechnology company’s stock worth $922,000 after buying an additional 15,000 shares in the last quarter. 78.93% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Ascendis Pharma A/S (ASND) Given a $50.00 Price Target at JPMorgan Chase & Co.” was first reported by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.mareainformativa.com/2018/01/30/ascendis-pharma-a-s-asnd-pt-set-at-50-00-by-jpmorgan-chase-co-updated-updated-updated.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.